

# MQS session

23<sup>th</sup> April 2024


# Agenda

1. Introduction of MQS
2. Survey on pharmaceutical supply
3. MQS session theme

# Agenda

1. Introduction of MQS
2. Survey on pharmaceutical supply
3. MQS session theme

# MQS Task force



Handle issues related pharmaceutical substances

ATIM  
Access To Innovative Medicines

12<sup>th</sup> APAC

MQS

# Agenda

1. Introduction of MQS
- 2. Survey on pharmaceutical supply**
3. MQS session theme

# Theme Selection

Due to the COVID-19 pandemic, the pharmaceutical supply chain has been greatly affected. While the stable supply of medicines is the responsibility of pharmaceutical companies for patients in need, events such as the spread of infectious diseases and natural disasters caused by climate change are expected to disrupt the supply chain in the future.



***MQS conducted a survey on the supply of medicines affected by COVID-19 to pharmaceutical industry.***

# Survey on pharmaceutical supply




## Summary of the survey

- Implementation period  
From mid-Sep. to mid-Oct.
- Respondents  
APAC association & JPMA members


# Survey on pharmaceutical supply

Q2 Have delays or disruptions in supply of raw materials affected manufacture of medicines ?

APAC associations



JPMA member companies



■ Yes  
■ No


Raw material supply issues have affected pharmaceutical production at many manufacturing sites in Asia and Japan.



# Survey on pharmaceutical supply


Q2-3 How were delays or disruptions in supply of raw materials addressed?

APAC associations



- Alternative suppliers
- Considering alternative suppliers
- Cooperation with suppliers
- Inventory and production adjustment
- Others

JPMA member companies




Addition of alternative suppliers were implemented or considered for supply issues.


# Survey on pharmaceutical supply

Q2-4 What measures do you need to take in future to avoid or mitigate risks?

APAC associations



JPMA member companies



Addition of alternative suppliers and securing stock is important as a future measure for supply issues.

# Survey on pharmaceutical supply



**The supply of pharmaceutical raw materials is the most critical issue.**

To address this problem, **securing second suppliers** and **streamlining additional procedures for alternative suppliers** were mentioned as possible solutions.

The full results of the survey will be published on the APAC website

***Thank you for your cooperation in the survey***

# Agenda

1. Introduction of MQS
2. Survey on pharmaceutical supply
3. MQS session theme

# Theme Selection

We recognize the importance for pharmaceutical companies to secure second suppliers even in normal times, **as part of their responsibilities to ensure the stable supply of medicines**. However, it may be **difficult to secure second suppliers for all raw materials** due to cost increases and regulations, etc.

In this MQS session, we would like to discuss **the support from the government related to the procedures for adding second suppliers** as an issue that pharmaceutical companies alone cannot cover, in order to **ensure the stable supply of medicines in times of crisis and to prepare for the future.**



## MQS session theme

Short time frame for additional supplier procedures

*We strive to not stop the supply of medicines for patients, no matter how difficult situation*

## Session contents

- Information sharing of useful case studies
- Panel discussion





**Thank you for your attention**